Evogene (EVGN) Stock Price, News & Analysis

Company Overview

Evogene Ltd. (NASDAQ: EVGN) is an Israel-based computational biology company that develops technologies and products designed to improve human health, agriculture and sustainability. The company uses artificial intelligence, machine learning and biological data analysis through its Computational Predictive Biology platform to identify and develop solutions based on biological mechanisms.

Evogene has built a portfolio of subsidiaries and business units focused on areas including agricultural biologicals, crop protection, microbiome-based therapeutics and medical cannabis. Its agricultural activities include the discovery and development of biological products such as bio-stimulants and biopesticides, while its human-health programs focus on microbiome-derived therapeutic candidates and related technologies. The company has also pursued collaborations and licensing arrangements with partners in its target markets.

Founded in 1998 and headquartered in Rehovot, Israel, Evogene serves global agriculture and life-sciences markets through partnerships, research collaborations and product-development programs. Ofer Haviv, a co-founder of the company, has served as Evogene’s president and chief executive officer.

Key Stats

• Today's Range: $0.35 to $0.38
• 50-Day Range: $0.27 to $0.55
• 52-Week Range: $0.25 to $1.26
• Volume: 2,488 shs
• Average Volume: 1.09 million shs
• Market Capitalization: $3.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Evogene Stock Analysis - MarketRank™

Evogene scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Evogene has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Evogene has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evogene are expected to grow in the coming year, from ($1.10) to ($0.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evogene is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evogene is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evogene has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.87% of the float of Evogene has been sold short.

Short Interest Ratio / Days to Cover

Evogene has a short interest ratio ("days to cover") of 2.33, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evogene has recently increased by 10.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evogene does not currently pay a dividend.

Dividend Growth

Evogene does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.45

News Sentiment

Evogene has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Evogene this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evogene insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.40% of the stock of Evogene is held by insiders.

Percentage Held by Institutions

10.40% of the stock of Evogene is held by institutions.

Company Calendar

• Today: 11/13/2026
• Next Earnings (Estimated): 11/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EVGN
• CIK: 1574565
• Web: www.evogene.com
• Phone: (728) 931-1900
• Fax: 972-8946-6724
• Employees: 52
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.48 million
• Net Margins: -694.18%
• Pretax Margin: -1,230.53%
• Return on Equity: -156.53%
• Return on Assets: -86.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.57
• Quick Ratio: 3.54

Sales & Book Value

• Annual Sales: $3.85 million
• Price / Sales: 0.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.37 per share
• Price / Book: 0.26

Miscellaneous

• Outstanding Shares: 8,720,000
• Free Float: 8,073,000
• Market Cap: $3.15 million
• Optionable: No Data
• Beta: 1.46